Johnson & Johnson - Articles and news items

Janssen Biotech, Inc. announces collaborative development and worldwide license agreement for investigational anti-cancer drug, PCI-32765

Industry news, News / 8 December 2011 / Johnson & Johnson

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765. A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. Interim data were reported at the 2011 American Society of Clinical Oncology Annual Meeting and oral presentations on two separate Phase 2 studies will be presented at the upcoming American Society of Hematology Meeting in December, along with several other poster presentations.

(more…)

STELARA® (Ustekinumab) is effective, well-tolerated and improves quality of life in patients with moderate to severe plaque psoriasis inadequately responsive to methotrexate[1,2]

Industry news, News / 21 October 2011 / Johnson and Johnson

New findings from the TRANSIT study were presented today at the 20th European Academy of Dermatology and Venereology (EADV) congress, which showed treatment with STELARA® (ustekinumab) is well-tolerated and effective in patients with moderate to severe plaque psoriasis inadequately responsive to methotrexate therapy.1 Health-related quality of life was also significantly improved according to the study results reported.2

(more…)

NUCYNTA® ER (Tapentadol Extended-Release Tablets) receives FDA approval

Industry news, News / 29 August 2011 / Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc. has announced the U.S. Food and Drug Administration (FDA) has approved NUCYNTA® ER, an oral analgesic taken twice daily, for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. (more…)

Greenphire Partners with Mytrus to provide web-based solutions

Featured news, News / 16 June 2011 / The Scott Partnership

Greenphire, the industry leading provider of clinical payment and communication technology solutions, has announced the partnership with Mytrus to deliver novel and efficient web-based solutions for clinical trial patients. In an industry characterized by timeless corporate giants like Johnson & Johnson, Pfizer, and Merck, two young technology companies are partnering to transform the clinical research environment. Recognizing longstanding deficiencies in the traditional clinical trials process, Greenphire LLC, based in Philadelphia and San Francisco startup Mytrus Inc. have developed web-based solutions to streamline the arduous and expensive tasks of recruiting, retaining, and efficiently administering clinical trials. Greenphire’s ClinCard System, a web-based patient payment, management and communication platform, compliments the functionality offered by Mytrus and its innovative methods for allowing patients to participate in clinical research studies directly from their own homes.

(more…)

Johnson & Johnson to buy orthopedic device maker Synthes for $21.3 billion

Industry news, News / 28 April 2011 / Johnson & Johnson

Johnson & Johnson (NYSE: JNJ), the world’s most comprehensive and broadly-based manufacturer of health care products, and Synthes, Inc. (SWX:SYST.VX), a premier global manufacturer of orthopaedic devices, today announced that they have entered into a definitive agreement whereby Johnson & Johnson will acquire Synthes for CHF159 per share, or $21.3 billion. Upon completion of this transaction, Synthes and the DePuy Companies of Johnson & Johnson together will comprise the largest business within the Medical Devices and Diagnostics segment of Johnson & Johnson. (more…)

Merck and Johnson & Johnson reach agreement on distribution rights for REMICADE® and SIMPONI®

Industry news, News / 15 April 2011 / Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc., today announced that the companies have reached agreement to amend the distribution rights to REMICADE® (infliximab) and SIMPONI® (golimumab), which treat chronic inflammatory diseases such as rheumatoid arthritis. This agreement concludes the arbitration proceeding Johnson & Johnson initiated in May 2009, requesting a ruling related to the distribution agreement following the announcement of the proposed merger between Merck and Schering-Plough.

(more…)

Johnson & Johnson announces settlement with U.S. Department of Justice and U.S. Securities and Exchange Commission

Industry news, News / 8 April 2011 / Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) announced today it will pay $70,006,316 in fines, disgorgement and interest, an amount previously reserved for, in a settlement related to publicly disclosed Foreign Corrupt Practices Act (FCPA) investigations by the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC). The Company hopes to reach a settlement of a related investigation by the U.K. Serious Fraud Office (SFO) in several days.

(more…)

Isogenica Ltd announces collaboration with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Industry news, News / 22 March 2011 / Limewash Media & Design Ltd

Isogenica Ltd today announced that it has executed a services agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“J&JPRD”).

(more…)

Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters

Industry news, News / 8 February 2011 / Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) provide further information regarding Johnson & Johnson’s proposed acquisition of Crucell.

(more…)

Janssen Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer’s Disease

Industry news, News / 1 December 2010 / Johnson & Johnson

Janssen Pharmaceutica N.V., (Janssen) today announced a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer’s disease prior to the onset of clinical symptoms. Pre-symptomatic biosignatures will allow earlier diagnosis of the disease and may enable significantly earlier intervention in Alzheimer’s disease.

(more…)

Applying PAT in pharmaceutical processes

Issue 5 2010 / 1 November 2010 / Mario Hellings, Tom Van den Kerkhof, Jeroen Geens and Steve Mehrman, Johnson & Johnson

As cited by the FDA, “Process Analytical Technology (PAT) is a system for designing, analysing, and controlling manufacturing through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality.”1 The main goal of PAT is to gain a deep understanding of manufacturing processes and to learn how to control them1. When processes are understood, opportunities for continuous improvement (quality and efficiency), cycle time reduction, cost reduction and QC lab test replacement arise. In this article, the strategy of Johnson & Johnson Pharmaceutical Research & Development (J&J PRD) towards the implementation of PAT in Pharmaceutical Process Development is explained and elucidated by case studies. (more…)

Pharmaceutical heads meet as manufacturing safety raises concern

Industry news / 18 October 2010 / Emma Naylor, NG Online News

Last week Pharmaceutical heads met as a result of a drugs recall after a pill mix up of breast cancer pills. The drug, Anastrozole, was made by Fresenius Kabi’s subsidiary in India. The ingredient mix up led to the voluntary recall of 7,192 bottles, each containing 30 tablets. (more…)